Streamlined Oncology Calculators & Survival Analysis
For clinical decision & research support.
Browse by Cancer Hub
Browse by Specialty
Myeloma Master Panel (R2-ISS & Frailty)
Integrates Disease Biology (R2-ISS) and Patient Fitness (IMWG) for treatment selection.
Febrile Neutropenia Triage
Combined MASCC and CISNE scores for risk stratification.
Palliative Survival Prediction
Survival estimates using PaP and PPI scores.
Liver & HCC Master Panel
Simultaneous calculation of Child-Pugh, ALBI, MELD-Na, BCLC, HKLC, and Milan Criteria.
Lung Nodule Malignancy Risk Panel
Comparison of Mayo, Brock (PanCan), and Herder models for pulmonary nodules.
Prostate Cancer Risk Stratification (NCCN & CAPRA)
Unified assessment using NCCN Guidelines (v4.2024), CAPRA Score, and Epstein Criteria.
Renal Cell Carcinoma (RCC) Prognosis Panel
Combined IMDC (Heng) and MSKCC (Motzer) risk stratification for metastatic RCC.
Lymphoma (DLBCL) Prognosis Panel
Combined Classic IPI, NCCN-IPI, aaIPI, CNS-IPI, and R-IPI for Diffuse Large B-Cell Lymphoma.
ECOG Performance Status
ECOG Performance Status quantifies functional capacity in cancer patients to determine treatment eligibility and dose modification needs.
Body Surface Area (BSA)
Body Surface Area calculator computes BSA using Du Bois or Mosteller formulas to determine accurate chemotherapy dosing in oncology patients.
Karnofsky Performance Status (KPS)
Karnofsky Performance Status scale (0-100) quantifies functional capacity in oncology patients to guide treatment eligibility and prognosis.
WHO Performance Status
WHO Performance Status scale classifies cancer patient functional ability from fully active to disabled to guide chemotherapy dosing decisions.
TNM Staging Recorder (Universal)
Universal TNM staging recorder documents tumor, node, and metastasis classifications for any cancer site per AJCC 8th edition guidelines.
Charlson Comorbidity Index
Charlson Comorbidity Index estimates 10-year survival by scoring 17 comorbid conditions and age to stratify mortality risk for treatment planning.
RMH Score (Phase I Trials)
Royal Marsden Hospital score stratifies advanced cancer patients using albumin, LDH, and metastatic sites to assess Phase I trial eligibility.
Khorana Score (VTE Risk)
Khorana score predicts venous thromboembolism risk in cancer patients starting chemotherapy to guide thromboprophylaxis prescribing decisions.
CUPI Score (Cancer of Unknown Primary)
CUPI score stratifies cancer of unknown primary into low- and high-risk groups using performance status, histology, and labs to guide therapy intensity.
EBV-DNA Prognostic Score (NPC)
EBV-DNA Prognostic Score integrates pre-treatment EBV DNA with TNM staging to stratify nasopharyngeal carcinoma survival and guide therapy.
MSKCC Pancreatic Cancer Nomogram
MSKCC Pancreatic Nomogram estimates disease-specific survival after pancreatic adenocarcinoma resection to guide adjuvant treatment planning.
Fistula Risk Score (FRS)
Fistula Risk Score predicts clinically relevant pancreatic fistula after pancreaticoduodenectomy to guide intraoperative drain placement decisions.
MSKCC Gastric Cancer Nomogram
MSKCC Gastric Cancer Nomogram estimates disease-specific survival after R0 gastrectomy to guide adjuvant chemotherapy decisions in gastric cancer.
JGCA Risk Classifier (EGC Curability)
JGCA criteria classify early gastric cancer endoscopic resection curability to determine if additional surgical gastrectomy is required.
Modified Glasgow Prognostic Score (mGPS)
Modified Glasgow Prognostic Score uses CRP and albumin to assess inflammation-based cancer prognosis and guide supportive care planning.
Glasgow Prognostic Score (Standard)
Glasgow Prognostic Score combines CRP and albumin to assess systemic inflammation and estimate cancer prognosis for treatment planning.
Fong Clinical Risk Score (CRS)
Fong Clinical Risk Score predicts recurrence after hepatic resection of colorectal liver metastases to guide postoperative surveillance planning.
Peritoneal Carcinomatosis Index (PCI)
Peritoneal Carcinomatosis Index quantifies tumor burden across 13 abdominal regions to evaluate candidacy for cytoreductive surgery and HIPEC.
NIH GIST Risk (Miettinen)
NIH GIST risk classification stratifies gastrointestinal stromal tumors by size and mitotic count to guide adjuvant imatinib therapy decisions.
AFIP GIST Risk (Miettinen)
AFIP Miettinen criteria stratify GIST progression risk by tumor size, mitotic rate, and anatomic location to guide surveillance and treatment.
Oncotype DX® Colon Recurrence Score
Oncotype DX Colon Recurrence Score estimates recurrence risk in stage II/III colon cancer to guide adjuvant chemotherapy decision-making.
Stage II Colon Cancer Risk Assessment
Stage II Colon Cancer Risk Assessment identifies high-risk pathologic features to guide adjuvant chemotherapy decisions per NCCN and ASCO guidelines.
PSDSS (Prostate Cancer-Specific Survival)
PSDSS stratifies survival in colorectal peritoneal metastases using symptoms, PCI, and histology to assess cytoreductive surgery candidacy.
GRIm Score
GRIm Score predicts overall survival on immune checkpoint inhibitors using albumin, LDH, and NLR to select immunotherapy candidates.
LIPI Score (Lung Immune)
LIPI Score stratifies metastatic NSCLC patients by dNLR and LDH to predict immunotherapy response and guide checkpoint inhibitor decisions.
Lung-RADS™ v2022
Lung-RADS v2022 categorizes pulmonary nodules on screening CT to standardize lung cancer risk assessment and guide follow-up intervals.
Small Cell Lung Cancer Staging (VALSG)
VALSG staging classifies Small Cell Lung Cancer as limited or extensive stage to determine eligibility for curative chemoradiation.
Solitary Pulmonary Nodule Malignancy Risk (Mayo)
Mayo Clinic model calculates malignancy probability for solitary pulmonary nodules to guide decisions on biopsy, resection, or CT surveillance.
Herder Model (Pulmonary Nodule)
Herder Model estimates malignancy probability in solitary pulmonary nodules using PET-CT results to guide biopsy or surveillance decisions.
Brock (PanCan) Nodule Risk
Brock PanCan model estimates lung cancer probability in pulmonary nodules detected on CT to guide biopsy versus surveillance decisions.
PLCOm2012 Lung Cancer Risk
PLCOm2012 model estimates 6-year lung cancer risk in ever-smokers to determine eligibility for low-dose CT screening per NCCN guidelines.
Masaoka-Koga Staging (Thymoma)
Masaoka-Koga staging classifies thymoma invasion depth to guide surgical resection planning and adjuvant therapy decisions in thymic tumors.
Mesothelioma EORTC Prognostic Index
EORTC Prognostic Index predicts survival in malignant pleural mesothelioma to guide decisions on multimodal therapy versus supportive care.
Mesothelioma CALGB Score
CALGB Mesothelioma Score stratifies malignant pleural mesothelioma prognosis to guide treatment intensity and clinical trial eligibility.
WHO CNS Tumor Grade (2021)
WHO 2021 CNS Tumor Grading classifies central nervous system tumors into grades 1-4 using histology and molecular markers to guide treatment.
RPA (Brain Metastases)
RTOG RPA classifies brain metastases patients into prognostic groups by age, KPS, and disease status to guide radiation treatment planning.
GPA (Graded Prognostic Assessment)
Graded Prognostic Assessment estimates median survival in brain metastases patients to guide whole-brain radiotherapy or surgical decisions.
Diagnosis-Specific GPA (Brain Mets)
Diagnosis-Specific GPA estimates survival in brain metastases from Lung, Breast, Melanoma, Renal, or GI primaries to guide radiation treatment planning.
Tokuhashi Score Calculator — Spine Metastases Surgical Prognosis
Calculate the revised Tokuhashi score for spinal metastases prognosis. Evaluate 6 prognostic parameters to guide surgical decision-making for vertebral metastatic disease.
Tomita Score (Spine Mets)
Tomita Score evaluates spinal metastases prognosis based on tumor grade and metastatic burden to guide surgical treatment strategy.
SINS (Spinal Instability)
SINS quantifies spinal instability from metastatic tumors using six clinical and radiographic factors to guide surgical consultation decisions.
NESMS (Epidural Spinal Cord)
NESMS predicts 1-year survival after surgical decompression for spinal metastases to guide operative versus palliative management decisions.
Mirels Score (Fracture Risk)
Mirels Score predicts pathologic fracture risk in metastatic long bone lesions to guide prophylactic surgical fixation versus radiotherapy.
Bauer Score (Bone Mets)
Bauer score estimates survival in spinal metastases patients to guide surgical versus palliative treatment decisions for bone metastases.
Katagiri Score (Bone Mets)
Katagiri score predicts survival in patients with skeletal metastases to guide palliative versus curative surgical intervention decisions.
FNCLCC Grade (Soft Tissue Sarcoma)
FNCLCC Grading assigns soft tissue sarcoma histologic grade based on differentiation, mitotic count, and necrosis to predict metastatic risk.
Enneking Staging (Bone/Sarcoma)
Enneking Staging classifies musculoskeletal sarcomas by grade, compartment, and metastasis to determine surgical resection margins.
HLH-2004 Diagnostic Criteria Calculator — Hemophagocytic Lymphohistiocytosis
Apply the HLH-2004 diagnostic criteria (5 of 8 criteria) for hemophagocytic lymphohistiocytosis. Systematic evaluation tool based on the Histiocyte Society diagnostic guidelines.
HScore for HLH
HScore calculates the probability of hemophagocytic lymphohistiocytosis (HLH) diagnosis to guide initiation of immunosuppressive therapy.
LCH Risk Organ Classification
LCH Risk Organ Classification stratifies Langerhans cell histiocytosis by system involvement to guide treatment intensity decisions.
Ann Arbor Staging (Histiocytic Sarcoma)
Ann Arbor staging classifies histiocytic sarcoma extent by nodal and extranodal involvement to guide treatment between localized and systemic.
Weiss Score (Adrenal)
Weiss Score evaluates nine histologic criteria to differentiate benign adrenocortical adenoma from malignant adrenocortical carcinoma.
PASS Score (Pheochromocytoma)
PASS Score differentiates benign from malignant pheochromocytoma using 12 histological features to guide adrenal tumor management decisions.
NET Grade / WHO 2019
WHO 2019 NET grading classifies neuroendocrine tumors by Ki-67 index and mitotic count to guide treatment selection and prognosis estimation.
MASCC Risk Index
MASCC Risk Index identifies low-risk febrile neutropenia patients in oncology to guide outpatient versus inpatient management decisions.
CARG Toxicity Score (Geriatric)
CARG Toxicity Score predicts Grade 3-5 chemotherapy toxicity risk in older adults (≥65y) to guide treatment intensity decisions in geriatric oncology.
G8 Screening Tool
G8 Geriatric Oncology Screening — quick 8-item assessment to identify elderly cancer patients needing comprehensive geriatric evaluation.
CISNE Score (Febrile Neutropenia)
CISNE score predicts serious complications in apparently stable febrile neutropenia to identify cancer patients safe for outpatient management.
Opioid Rotation & OME Calculator
Opioid Rotation Calculator performs evidence-based equianalgesic conversion with NCCN safety protocols for cancer pain management and dose adjustment.
ESAS-R Calculator — Edmonton Symptom Assessment System Revised
ESAS-R (Edmonton Symptom Assessment System Revised) calculator for palliative care. Assess 10 common cancer symptoms including pain, fatigue, nausea, and anxiety on a 0-10 scale.
PaP Score (Palliative Prognosis)
PaP Score predicts 30-day survival probability in advanced cancer palliative care patients to stratify end-of-life treatment intensity.
Palliative Prognostic Index (PPI)
Palliative Prognostic Index predicts weeks-to-months survival in terminal cancer patients using clinical symptoms without blood tests.
NCCN-IPI (Lymphoma)
NCCN-IPI stratifies diffuse large B-cell lymphoma into four prognostic risk groups to guide rituximab-era chemoimmunotherapy treatment intensity.
CLL-IPI
CLL-IPI stratifies 5-year overall survival in Chronic Lymphocytic Leukemia using TP53, IGHV, beta-2 microglobulin, stage, and age to guide therapy.
MIPI (Mantle Cell Lymphoma)
MIPI calculates prognosis in advanced mantle cell lymphoma using age, ECOG, LDH, and WBC to guide treatment intensity and trial selection.
IPS (Hodgkin Lymphoma)
IPS (Hasenclever) predicts progression-free survival in advanced Hodgkin lymphoma to guide escalation of first-line chemotherapy regimens.
IPS-7 (Adult Hodgkin Lymphoma)
International Prognostic Score (IPS-7) for advanced Hodgkin lymphoma — 7-factor risk stratification to guide ABVD vs intensified regimens.
CHIPS (Childhood Hodgkin Score)
CHIPS score stratifies pediatric Hodgkin Lymphoma risk to guide treatment intensification or de-escalation based on stage, bulk, and B-symptoms.
DIPSS (Myelofibrosis)
DIPSS estimates survival in Primary Myelofibrosis at any disease timepoint using age, blood counts, blasts, and symptoms to guide transplant decisions.
DIPSS-Plus (Myelofibrosis)
DIPSS-Plus refines Primary Myelofibrosis prognosis by adding karyotype, platelet count, and transfusion status to stratify transplant candidacy.
IPSSWM (Waldenström)
IPSSWM stratifies Waldenstrom macroglobulinemia patients into prognostic risk groups to guide initiation of chemoimmunotherapy treatment.
IPSET-Thrombosis (Essential Thrombocythemia)
IPSET-Thrombosis score stratifies thrombotic risk in essential thrombocythemia patients to guide aspirin and cytoreductive therapy decisions.
ELTS Score (CML)
ELTS Score estimates long-term CML-specific survival risk in chronic myeloid leukemia patients on TKI therapy to guide treatment intensity.
SANZ Risk Score (APL)
Sanz Risk Score stratifies APL patients by WBC and platelet count to guide ATRA-based treatment intensity in Acute Promyelocytic Leukemia.
HCT-CI (Transplant Risk)
HCT-CI (Sorror Score) quantifies comorbidity burden to stratify non-relapse mortality risk before allogeneic hematopoietic cell transplantation.
R-ISS (Multiple Myeloma)
R-ISS stages newly diagnosed multiple myeloma using albumin, beta-2 microglobulin, LDH, and cytogenetics to stratify 5-year survival prognosis.
FLIPI (Follicular Lymphoma)
FLIPI predicts overall survival in follicular lymphoma using five prognostic factors to stratify patients into low, intermediate, or high risk.
IPSS-R for MDS
IPSS-R stratifies myelodysplastic syndrome patients by survival and AML transformation risk to guide transplant and treatment timing.
International Prognostic Index (IPI)
International Prognostic Index predicts overall survival in diffuse large B-cell lymphoma to guide R-CHOP chemotherapy intensity decisions.
ALBI Score
ALBI score grades hepatocellular carcinoma liver function using albumin and bilirubin levels to stratify prognosis and guide HCC treatment.
ALBI-T Score
ALBI-T score combines liver function grade with tumor TNM stage to stratify hepatocellular carcinoma prognosis and guide treatment selection.
BCLC Staging System (2022 Update)
BCLC 2022 staging classifies hepatocellular carcinoma by tumor burden, liver function, and performance status to guide HCC treatment strategy.
HKLC Staging System
HKLC staging classifies hepatocellular carcinoma patients into treatment groups to guide resection, TACE, or systemic therapy selection.
CNLC Staging (China)
CNLC staging classifies hepatocellular carcinoma by tumor extent, liver function, and performance status to guide resection, TACE, or systemic therapy.
JIS Score (Japan Integrated Staging)
JIS score integrates Child-Pugh liver function and Japanese TNM stage to stratify survival prognosis in hepatocellular carcinoma patients.
Child-Pugh Score
Child-Pugh Score classifies cirrhosis severity into Class A, B, or C to estimate survival and guide liver transplant or hepatic surgery decisions.
MELD Score
MELD Score calculates end-stage liver disease severity using bilirubin, creatinine, and INR to prioritize patients for liver transplantation.
Milan Criteria
Milan Criteria evaluate HCC tumor burden to determine liver transplant eligibility and guide treatment selection for hepatocellular carcinoma.
CLIP Score
CLIP score estimates hepatocellular carcinoma survival by integrating Child-Pugh stage, tumor morphology, AFP, and portal vein thrombosis status.
LI-RADS® v2018 (CT/MRI)
LI-RADS v2018 classifies liver observations on CT/MRI to estimate HCC probability and guide diagnostic workup in at-risk patients.
IMDC (Heng) Risk Criteria Calculator — Metastatic Renal Cell Carcinoma
Calculate the IMDC/Heng risk score for metastatic renal cell carcinoma. Evaluate 6 prognostic factors to classify patients as favourable, intermediate, or poor risk for first-line therapy selection.
MSKCC (Motzer) Score
MSKCC (Motzer) Score stratifies metastatic renal cell carcinoma into risk groups to guide first-line systemic therapy selection for mRCC patients.
Leibovich Score (RCC)
Leibovich Score predicts metastasis-free survival after nephrectomy for clear cell renal cell carcinoma to guide surveillance planning.
SSIGN Score (Mayo)
SSIGN Score predicts cancer-specific survival in clear cell renal cell carcinoma using pathologic stage, tumor size, nuclear grade, and necrosis.
UISS (UCLA Integrated Staging)
UISS stratifies localized renal cell carcinoma into risk groups using TNM stage, Fuhrman grade, and ECOG to predict post-nephrectomy survival.
BI-RADS Score (Breast)
BI-RADS classifies breast imaging findings into risk categories to standardize reporting and guide biopsy or surveillance management decisions.
Nottingham Prognostic Index (NPI)
Nottingham Prognostic Index calculates invasive breast cancer prognosis using tumor size, grade, and nodal status to guide adjuvant therapy.
MSKCC DCIS Nomogram — Breast Cancer DCIS Recurrence Risk Calculator
Calculate DCIS recurrence risk using the Memorial Sloan Kettering (MSKCC) nomogram. Estimate 5 and 10-year local recurrence probability after breast-conserving surgery for ductal carcinoma in situ.
Van Nuys Prognostic Index (USC-VNPI)
Van Nuys Prognostic Index (VNPI) — evidence-based DCIS scoring for treatment decisions: excision alone, excision + radiation, or mastectomy.
CPS+EG Score
CPS+EG score estimates distant metastasis-free survival in breast cancer after neoadjuvant chemotherapy to stratify post-treatment prognosis.
Allred Score for ER/PR
Allred score quantifies ER and PR hormone receptor staining in breast cancer to determine endocrine therapy eligibility and predict response.
Magee Equation (Est. Oncotype DX®)
Magee Equation estimates Oncotype DX Recurrence Score from standard breast cancer pathology to guide decisions on genomic testing need.
AJCC Prognostic Stage (Breast)
AJCC 8th edition breast cancer staging integrates anatomic TNM with ER, PR, HER2, and grade to classify prognostic stage and guide therapy.
Residual Cancer Burden (RCB)
Residual Cancer Burden score quantifies remaining breast tumor after neoadjuvant chemotherapy to classify pathologic response and guide adjuvant care.
PREDICT Breast (Prognostic Index)
PREDICT Breast estimates survival benefit of adjuvant chemotherapy, endocrine therapy, and trastuzumab in early invasive breast cancer.
Gail Model (Relative Risk)
Gail Model estimates 5-year and lifetime relative risk of invasive breast cancer to identify candidates for chemoprevention with tamoxifen.
Oncotype DX Recurrence Score Calculator — Breast Cancer Genomic Risk
Interpret your Oncotype DX 21-gene recurrence score for HR+/HER2- breast cancer. Understand risk category and chemotherapy benefit based on TAILORx and RxPONDER trial evidence.
MammaPrint Interpreter
MammaPrint Interpreter classifies 70-gene breast cancer assay results to guide chemotherapy de-escalation decisions per MINDACT trial data.
Prosigna / PAM50 Interpreter
Prosigna PAM50 interprets Risk of Recurrence score to stratify 10-year distant recurrence risk in HR+/HER2- early-stage breast cancer.
EndoPredict (EPclin) Interpreter
EndoPredict EPclin Score stratifies early and late distant recurrence risk in ER+/HER2- breast cancer to guide chemotherapy decisions.
Breast Cancer Index (BCI)
Breast Cancer Index predicts late distant recurrence risk and evaluates benefit of extending endocrine therapy beyond 5 years in HR+ breast cancer.
D'Amico Risk Classification
D'Amico classification stratifies localized prostate cancer into Low, Intermediate, or High risk using PSA, Gleason, and stage to guide treatment.
Epstein Criteria (Insignificant Cancer)
Epstein Criteria evaluate PSA density, Gleason score, and core data to identify clinically insignificant prostate cancer for active surveillance.
PI-RADS™ v2.1 (Prostate MRI)
PI-RADS v2.1 stratifies prostate MRI lesions by likelihood of clinically significant cancer to guide biopsy decision-making in urology.
Gleason Score & ISUP Grade
Gleason Score calculator converts primary and secondary biopsy patterns into ISUP Grade Groups to stratify prostate cancer aggressiveness.
CAPRA Score
CAPRA score predicts prostate cancer recurrence after radical prostatectomy using PSA, Gleason, and stage to stratify pre-operative risk.
CAPRA-S Score (Post-Surgical)
CAPRA-S score predicts biochemical recurrence after radical prostatectomy using pathologic data to guide adjuvant prostate cancer treatment.
Decipher® Prostate Risk
Decipher Genomic Classifier interprets the 22-gene prostate cancer score to predict metastasis risk and guide adjuvant or salvage radiotherapy decisions.
Prolaris® (CCP Score)
Prolaris CCP Score assesses prostate cancer aggressiveness via cell cycle gene expression to guide active surveillance or treatment decisions.
Oncotype DX® GPS (Prostate)
Oncotype DX GPS assesses prostate cancer genomic aggressiveness to guide active surveillance versus definitive treatment decisions.
ProMark® Proteomic Score
ProMark proteomic assay predicts aggressive pathology risk in prostate cancer biopsies to support active surveillance versus treatment decisions.
EORTC NMIBC Risk Calculator — Bladder Cancer Recurrence & Progression
Calculate non-muscle invasive bladder cancer (NMIBC) recurrence and progression risk using the EORTC scoring system. Evidence-based risk stratification for clinical decision-making.
CUETO Risk Score (BCG-Treated)
CUETO score predicts 5-year recurrence and progression risk in non-muscle invasive bladder cancer patients treated with BCG immunotherapy.
EAU NMIBC Risk Stratification (2024)
EAU NMIBC Risk Stratification classifies bladder cancer into Low to Very High risk groups to guide BCG therapy and cystectomy decisions.
IGCCCG Risk Classification (2021 Update)
IGCCCG classification stratifies metastatic germ cell tumors into risk groups to guide platinum-based chemotherapy regimen selection.
MSKCC Stage I NSGCT Nomogram
MSKCC NSGCT Nomogram predicts occult retroperitoneal metastasis risk in clinical stage I non-seminoma to guide surveillance versus RPLND decisions.
FIGO GTN Risk Score
FIGO GTN Risk Score stratifies gestational trophoblastic neoplasia into low or high risk to guide single-agent vs multi-agent chemotherapy.
RMI (Risk of Malignancy Index)
Risk of Malignancy Index estimates ovarian cancer probability in adnexal masses using CA125, ultrasound, and menopausal status for triage.
ROMA Score (Ovarian)
ROMA score combines HE4 and CA125 biomarkers with menopausal status to stratify ovarian malignancy risk and guide surgical referral decisions.
AGO Score (DESKTOP)
AGO DESKTOP score predicts complete resection likelihood in recurrent ovarian cancer to guide secondary cytoreductive surgery decisions.
iMODEL (Ovarian Recurrence)
iMODEL Score — predict complete cytoreduction (R0) probability in platinum-sensitive recurrent ovarian cancer. 6-factor risk model.
O-RADS Calculator — Ovarian-Adnexal Reporting & Data System (Ultrasound)
O-RADS ultrasound calculator for ovarian and adnexal mass risk stratification. Classify lesions from O-RADS 1 (normal) to O-RADS 5 (high risk) based on ACR criteria.
ESGO/ESTRO/ESP Endometrial Risk (2021)
ESMO 2021 Risk Classification stratifies endometrial cancer by stage, grade, and LVSI to guide adjuvant radiotherapy and chemotherapy decisions.
Mayo Criteria (Endometrial)
Mayo Criteria predict lymph node metastasis risk in endometrial cancer to guide surgical staging and lymphadenectomy decision-making.
Sedlis Criteria (Cervical)
Sedlis Criteria evaluate intermediate-risk cervical cancer patients after hysterectomy to determine the need for adjuvant pelvic radiation therapy.
Moore Criteria (Advanced Cervical)
Moore Criteria predict survival in recurrent or metastatic cervical cancer to guide cisplatin-based chemotherapy regimen selection decisions.
Sentinel Lymph Node Risk (Melanoma)
Estimates sentinel lymph node positivity risk in melanoma based on Breslow depth, ulceration, and age to guide biopsy decision-making.
MACIS Score (Thyroid)
MACIS Score estimates 20-year cause-specific survival in papillary thyroid carcinoma to guide postoperative risk stratification decisions.
ATA Risk Stratification (Thyroid)
ATA risk stratification classifies differentiated thyroid cancer recurrence risk to guide post-surgical surveillance and TSH suppression targets.
About OncoToolkit: Your Comprehensive Oncology Calculator Resource
OncoToolkit provides healthcare professionals with a comprehensive suite of evidence-based oncology calculators, staging systems, and prognostic tools. Our platform supports clinical decision-making across all major cancer types, from initial diagnosis through treatment planning and follow-up care.
Comprehensive Cancer Staging & Prognosis Tools
Access validated scoring systems including ECOG and Karnofsky Performance Status for functional assessment, Child-Pugh and ALBI scores for liver function evaluation, and tumor-specific staging calculators following AJCC/UICC guidelines. Our tools cover breast cancer (Oncotype DX, NPI), prostate cancer (Gleason, CAPRA), lung cancer (TNM staging, GPA), and many more.
Treatment Decision Support
Make informed treatment decisions with calculators designed to assess treatment eligibility, predict response, and evaluate toxicity risk. From chemotherapy dosing based on BSA calculations to immunotherapy eligibility assessment, our tools help optimize patient outcomes while minimizing adverse events.
Evidence-Based Clinical Tools
Every calculator on OncoToolkit is based on peer-reviewed research and validated in clinical practice. We provide transparent methodology with references to original publications, ensuring you understand the evidence behind each tool. Explore our oncology glossary for terminology definitions and video tutorials about how to use this app.
OncoToolkit is for educational and clinical decision support purposes only. Always verify results with current clinical guidelines and institutional protocols.